

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT7342301

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
ACADEMIC PHARMACEUTICALS, INC.	12/23/2021
RECEIVING PARTY DATA	
Name:	HYLORIS DEVELOPMENTS S.A.
Street Address:	BOULEVARD GUSTAVE KLEYER 17
City:	LIÈGE
State/Country:	BELGIUM
Postal Code:	4000
PROPERTY NUMBERS Total: 11	
Property Type	Number
Application Number:	12077008
Application Number:	13076297
Application Number:	13717680
Application Number:	62557210
Application Number:	16640964
Application Number:	62689442
Application Number:	16449796
Application Number:	17380413
Application Number:	62704557
Application Number:	63199426
PCT Number:	US2018050340
CORRESPONDENCE DATA	
Fax Number:	(208)979-0707
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	434-531-5976
Email:	David@VancelP.biz
Correspondent Name:	VANCEIP
Address Line 1:	PO BOX 1224
Address Line 4:	CROZET, VIRGINIA 22932

ATTORNEY DOCKET NUMBER:	APH-004-014-015-017
NAME OF SUBMITTER:	DAVID H VANCE
SIGNATURE:	/David H Vance/
DATE SIGNED:	05/20/2022
Total Attachments: 3 source=Assignment signed 3 pages-JS to Hyloris-004-014-015-017#page1.tif source=Assignment signed 3 pages-JS to Hyloris-004-014-015-017#page2.tif source=Assignment signed 3 pages-JS to Hyloris-004-014-015-017#page3.tif	

Docket No. APH-004, 014, 015, 017

ASSIGNMENT

WHEREAS, the undersigned, to wit:

ACADEMIC PHARMACEUTICALS, INC., (hereinafter ASSIGNOR), has obtained the entire right, title, and interest in and to certain new and useful inventions and improvements disclosed in the following applications:

SEE SCHEDULE A;

AND WHEREAS, **Hyloris Developments S.A.**, (a Belgian Corporation)(hereinafter ASSIGNEE), of Boulevard Gustave Kleyer 17, 4000 Liège, Belgium, is desirous of obtaining the entire right, title and interest in and to the inventions, improvements, and the applications and any Patents that may issue therefrom; including the right to claim priority thereof.

NOW THEREFORE, pursuant to contractual obligations heretofore assumed by us and for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, ASSIGNOR does hereby assign and transfer unto ASSIGNEE, its successors, assigns, and legal representatives ASSIGNOR's entire right, title, and interest in and to the inventions, improvements, applications that may be filed therefrom, and patents that may be granted therefrom throughout the world, including: (a) the right to file additional applications and obtain patents, utility models, industrial models, and designs for the inventions and improvements in ASSIGNEE'S own name throughout the world; (b) all rights to publish cautionary notices reserving ownership of the inventions and improvements; (c) all rights to register the inventions and improvements in appropriate registries; and, (d) the right, title, and interest in all divisions, reissues, substitutions, continuations, continuations-in-part, and extensions thereof, (e) the right to claim priority from earlier filings.

ASSIGNOR hereby authorizes and requests the Commissioner of Patents and Trademarks or similar appropriate authority to issue all patents for the inventions and improvements, insofar as ASSIGNOR's interest is concerned, to the ASSIGNEE.

ASSIGNOR hereby further agrees to execute any and all powers of attorney, applications, assignments, declarations, affidavits, and any other papers in connection therewith necessary to perfect such rights, title and interest in ASSIGNEE, its successors, assigns, and legal representatives.


ASSIGNOR hereby further agrees to communicate with the ASSIGNEE, or its successors, assigns, and legal representatives, any facts known to ASSIGNOR respecting any improvements; and, at the expense of the ASSIGNEE, to testify in any legal proceedings, sign all lawful papers, execute all divisional, continuation, continuation-in-part, reissue, and substitute applications, make all lawful oaths, and generally do everything possible to vest title in the ASSIGNEE and to aid the ASSIGNEE, its successors, assigns, and legal representatives to obtain and enforce proper protection for the inventions and improvements in all countries.



ASSIGNOR hereby grants the firm of **VANCE INTELLECTUAL PROPERTY, PC** and its agents the power to insert on this assignment any further identification, including but not limited to application numbers and filing dates, which may be necessary or desirable in order to comply with any rule or request of the United States Patent and Trademark Office or other country or regional patent office for the purposes of recording this document.


ASSIGNEE hereby accepts the assignment and transfer.

Executed on the date(s) below indicated:



John Somberg
President
Academic Pharmaceuticals, Inc.

23 Dec 2021
Date



Thomas Jacobsen
Chief Business Development Officer
Hyloris Developments S.A.

22nd Dec. 2021
Date

SCHEDULE A

FILE #	TITLE	COUNTRY	APPLICATION #	DATE FILED	PATENT #
APH-004-US	PARENTERAL SOLUTIONS CONTAINING METOLAZONE	USA	12/077,008	Mar 17, 2008	7923447
APH-004-US-CNT2	PARENTERAL SOLUTIONS CONTAINING METOLAZONE	USA	13/717,680	Dec 17, 2012	9427398
APH-014-CA	METOLAZONE EMULSION FORMULATION	Canada	3,073,527	Sep 11, 2018	
APH-014-EP	METOLAZONE EMULSION FORMULATION	EPO	18856454.6	Sep 11, 2018	
APH-014-US	METOLAZONE EMULSION FORMULATION	USA	16/640,964	Sep 11, 2018	
APH-015-US	A METHOD OF INITIATING OR ESCALATING DOFETILIDE DOSE AND FORMULATIONS THEREFOR	USA	16/449,796	Jun 24, 2019	
APH-015-US-DIV1	A METHOD OF INITIATING OR ESCALATING DOFETILIDE DOSE AND FORMULATIONS THEREFOR	USA	17/380,413	Jul 20, 2021	
APH-017-P2	TICAGRELOR INTRAVENOUS FORMULATIONS	USA	63/199,426	Dec 27, 2020	